Muñoz-Langa, J. http://orcid.org/0000-0002-6942-8916
Jimenez-Fonseca, P.
Carmona-Bayonas, A.
de Castro, E. M.
Pérez-Segura, P.
Cánovas, M. S.
Gomez, D.
Moran, L. O.
de Tejada, M. B G.
Seguí, E.
López, G. B.
Adrián, S. G.
Campos, M. C.
Olmos, V. P.
Portero, B. O.
Moyano, M. S.
Crespo, J. A. S.
Sánchez, L. T.
Rebollo, M. A.
Rivas, P. O.
Altozano, J. P.
Lescure, Á. R.
Muñoz-Martín, A.
Funding for this research was provided by:
Sanofi España
Article History
Received: 7 May 2020
Accepted: 3 August 2020
First Online: 13 August 2020
Compliance with ethical standards
:
: JML: consultant or Advisory Role: LEO Pharma. Sanofi. Rovi. Speaking: Sanofi, LeoPharma, Rovi. Travel, Accommodations: LeoPharma, Sanofi. PJF: consultant or advisory role: Roche, Bristol, Mylan, Rovi, Sanofi, LeoPharma; travel grants: Ipsen. ACB: consultant or advisory role: Roche, Rovi, Sanofi, LeoPharma, Pfizer, Esteve; travel grants: Ipsen, Roche, Novartis. EMC: consultant or Advisory Role: Pfizer, Amgen. Speaking: Roche, Pfizer, Amgen, Sanofi, LeoPharma, Rovi, Celgene. Travel, Accommodations: Roche, Pfizer, Celgene, Sanofi. PPS: consultant or Advisory Role: Novartis, BMS, Merck. Travel, Accommodations: MSD, Merck. MSC: consultant or Advisory Role: KyowaKirin. Research Funding: LeoPharma. Financial support for educational programs: Angelini, Sanofi, Rovi, LeoPharma, Servier. Remunerations for authorship: KyowaKirin, Mylan. Travel, Accommodations: Sanofi, MSD, Esteve, Amgen, Servier, Angelini, Leo Pharma. DG: None. LOM: consultant or Advisory Role: Sanofi. Speaking: Amgen, Sanofi, Leo-Pharma. Travel, Accommodations: Roche, Amgen, Sanofi, LeoPharma. MBGT: Speaker: Rovi, Leo Pharma, Sanofi, Sponsored Academic Activities: Rovi, Leo Pharma. ES: None. GBL: None. SGA: consultant/advisory honorarium Eisai, Celgene, Roche, Pierre Fabre, Novartis, Sanofi Aventis and Astra Zeneca. MCC: consultant/advisory Role: Leo pharma. Speaking: Rovi. VPO: Advisory board: Daichi. Speaking: Sanofi, Leo-Pharma. BOP: none. MSM: none. JASC: advisory board; Sanofi, Servier. LTS: none. MAR: none. POR: none. JPA: none ARL: Consultant or Advisory Role: Roche, Pfizer, Novartis, Lilly, Mylan. Speaking: Roche, Pfizer, Novartis, Lilly, Kern, A-Z, Mylan, Eisai. Travel, Accommodations (ASCO, SABCS): Roche, Novartis. Research Funding To my Institution: Roche, Novartis, Pfizer, Lilly, Astra-Zeneca, Amgen, MSD. AM: consulting, lectures and advisory board: Sanofi, Celgene, Astra-Zeneca, Roche, Leo Pharma, Servier, Pfizer, Bristol-Myers Squibb, Daiichi Sankyo, Bayer, Halozyme, Amgen, Rovi, Merck Sharp & Dohme and Lilly. Research funding: Sanofi, LEO Pharma, Celgene. Travel, Accommodations: Roche, Merck Serono, Amgen, Celgene. All outside of the scope of this work.
: All procedures followed are in accordance with the ethical standards of the committee in charge of human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions.
: was obtained from all patients before they were included in the study.